RealTime Dynamix™: Inflammatory Bowel Disease US Q3 2017 Remicade is considered by many as the go-to agent for treating IBD (Crohn’s disease and Ulcerative Colitis), but the introduction and adoption of TNF-inhibiting biosimilars is starting to shake up the IBD biologics market, according to RealTime Dynamix™: Inflammatory Bowel Disease US Q3, a survey of 103 US gastroenterologists fielded in August 2017. Highlights from this report: Though use of the available infliximab biosimilars (Pfizer’s Inflectra and Merck/Samsung Bioepis’ Renflexis) is on the rise and is projected to increase, US gastroenterologists are still on the fence regarding use of biosimilars. However, as additional TNF inhibiting biosimilars become available, such as, Sandoz’s Erelzi (etanercept), Amgen’s Amjevita (adalimumab), and Boehringer Ingelheim’s recently approved Cyltezo (adalimumab), it is anticipated that insurance mandates for biosimilar use will become increasingly common. Result of Contact from Pharmacist/Insurance Company Regarding Inflectra Statement Agreement Levels “I think the availability of biosimilars for IBD is a good thing for patients.” “As more TNF biosimilars become available, the use of alternative MOAs will increase.” The leading barrier to increased use of infliximab biosimilars appears to be apathy rather than clinical concerns. GIs report that in the majority of cases they are not being pushed to change. 19% of respondents indicated another result, including “starting new patients on Inflectra” and “patients will be switched soon” RealTime Dynamix™: IBD US is a quarterly report series providing insights about the evolving IBD market. Participating gastroenterologists are recruited from the Spherix Network, a proprietary panel of more than 400 gastroenterologists managing at least 50 patients with IBD. For more information contact: [email protected]14% 20% Percent of Gastroenterologists Contacted by a Pharmacist/Insurance Company Regarding Use of Inflectra Over Branded Remicade As payer pressure is likely to increase, six month projections of the CD and UC biologic market reveal continued erosion of the leading TNF brands, in favor of significant gains for biosimilars and biologics with alternative MOAs.
2
Embed
RealTime Dynamix™: Inflammatory Bowel Disease US Q3 2017 · RealTime Dynamix™: Inflammatory Bowel Disease US Q3 2017 Remicade is considered by many as the go-to agent for treating
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
RealTime Dynamix™: Inflammatory Bowel Disease US Q3 2017
Remicade is considered by many as the go-to agent for treating IBD (Crohn’s disease and Ulcerative
Colitis), but the introduction and adoption of TNF-inhibiting biosimilars is starting to shake up the IBD
biologics market, according to RealTime Dynamix™: Inflammatory Bowel Disease US Q3, a survey of
103 US gastroenterologists fielded in August 2017. Highlights from this report:
Though use of the available infliximab biosimilars (Pfizer’s Inflectra and Merck/Samsung Bioepis’ Renflexis) is on
the rise and is projected to increase, US gastroenterologists are still on the fence regarding use of biosimilars.
However, as additional TNF inhibiting biosimilars become available, such as, Sandoz’s Erelzi (etanercept),
Amgen’s Amjevita (adalimumab), and Boehringer Ingelheim’s recently approved Cyltezo (adalimumab), it is
anticipated that insurance mandates for biosimilar use will become increasingly common.
Result of Contact from Pharmacist/Insurance Company Regarding Inflectra
Statement Agreement Levels
“I think the availability of biosimilars for IBD is a good thing for patients.”
“As more TNF biosimilars become available, the use of alternative MOAs will increase.”
The leading barrier to increased use of infliximab biosimilars appears to be apathy rather than clinical concerns. GIs report that in the majority of cases they are not being pushed to change.
19% of respondents indicated another result, including “starting
new patients on Inflectra” and “patients will be switched soon”
RealTime Dynamix™: IBD US is a quarterly report series providing insights about the evolving IBD market. Participating gastroenterologists are recruited from the Spherix Network, a proprietary panel of more than 400 gastroenterologists managing at least 50 patients with IBD. For more information contact: [email protected]
14%
20%
Percent of Gastroenterologists Contacted by a Pharmacist/Insurance Company Regarding Use
of Inflectra Over Branded Remicade
As payer pressure is likely to increase, six month projections
of the CD and UC biologic market reveal continued erosion
of the leading TNF brands, in favor of significant gains for